Spots Global Cancer Trial Database for lung cancer metastatic
Every month we try and update this database with for lung cancer metastatic cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography in Metastatic Non-Small Cell Lung Cancer | NCT05452005 | Lung Cancer Lung Cancer Met... Brain Metastase... Non Small Cell ... | [18F]-αvβ6-BP | 18 Years - | University of California, Davis | |
| DBT for Metastatic Lung Cancer | NCT04973436 | Lung Cancer Met... | Dialectical Beh... | 18 Years - | Duke University | |
| DBT for Metastatic Lung Cancer | NCT04973436 | Lung Cancer Met... | Dialectical Beh... | 18 Years - | Duke University | |
| A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs | NCT06228326 | Lung Cancer, No... Lung Cancer Met... Solid Tumor, Ad... Advanced Cancer Lung Cancer, Sm... Metastatic Colo... Metastatic Rena... Metastatic Hepa... Metastatic Sarc... Metastatic Oste... | KB707 | 18 Years - | Krystal Biotech, Inc. | |
| Capmatinib in Patients With Non-small Cell Lung Cancer Harboring cMET exon14 Skipping Mutation | NCT03693339 | Cancer Lung Cancer Met... MET Gene Mutati... | Capmatinib | 18 Years - | Asan Medical Center | |
| Dabrafenib and Trametinib in Patients With Non-small Cell Lung Cancer Harboring V600E BRAF Mutation | NCT03543306 | Cancer Lung Cancer Met... BRAF V600E | daborafenib plu... | 18 Years - | Asan Medical Center | |
| Neck Ultrasound by Respiratory Physicians in Patients With Lung Cancer | NCT03970564 | Lung Cancer Met... Nodes, Lung | Neck ultrasound... | - | University College Hospital Galway | |
| Early Palliative Care in Metastatic Lung Cancer in Northern France | NCT02308865 | Lung Cancer Met... | multi disciplin... | 18 Years - | University Hospital, Lille | |
| Feasibility of Wearable Activity Trackers for Detection of TOXicity in People Receiving Systemic Anticancer Treatment | NCT04440800 | Lung Cancer, Sm... Pancreatic Canc... Gastric Cancer Oesophageal Can... Lung Cancer, No... Lung Cancer Met... | Wearable activi... | 18 Years - | Royal Marsden NHS Foundation Trust | |
| Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC | NCT04069936 | Non Small Cell ... Lung Cancer Lung Cancer Met... Lung Cancer, No... Non Small Cell ... NSCLC Non-small Cell ... Non-small Cell ... | MILs™ - NSCLC nivolumab tadalafil | 18 Years - | WindMIL Therapeutics | |
| Capmatinib in Patients With Non-small Cell Lung Cancer Harboring cMET exon14 Skipping Mutation | NCT03693339 | Cancer Lung Cancer Met... MET Gene Mutati... | Capmatinib | 18 Years - | Asan Medical Center | |
| Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC | NCT03184571 | Lung Cancer Met... NSCLC Stage IV Adenocarcinoma ... | Bemcentinib; pe... | 18 Years - | BerGenBio ASA | |
| A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib | NCT03076164 | Lung Adenocarci... Lung Cancer Lung Cancer Met... Lung Cancer Sta... Recurrent Lung ... Recurrent Lung ... | Trametinib Erlotinib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers | NCT05860296 | Lung Cancer, No... Lung Cancer Sta... Lung Cancer Met... | SLC-391 pembrolizumab | 18 Years - | SignalChem Lifesciences Corporation | |
| The Alterations of Metabolic Adipo-myokines and Body Composition in End Stage Lung Cancer | NCT06060262 | Lung Cancer Met... | 20 Years - 100 Years | Chang Gung Memorial Hospital | ||
| Dabrafenib and Trametinib in Patients With Non-small Cell Lung Cancer Harboring V600E BRAF Mutation | NCT03543306 | Cancer Lung Cancer Met... BRAF V600E | daborafenib plu... | 18 Years - | Asan Medical Center | |
| Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients With Metastatic Cancer in Response After 6 Months of Standard IO | NCT05078047 | Lung Cancer Met... Renal Cell Carc... Head and Neck C... Bladder Cancer Triple Negative... Merkel Cell Car... Hepatocellular ... Melanoma | Reduced dose in... | 18 Years - | UNICANCER | |
| Needlescopic-assisted Uniportal vs Uniportal VATS | NCT03439696 | Lung Cancer Lung Cancer Met... Bullous Disease... Nodule Solitary... Mediastinal Tum... | Thoracoscopic s... | 20 Years - 90 Years | National Taiwan University Hospital Hsin-Chu Branch | |
| A Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Naïve Patients With Metastatic NSCLC | NCT05144529 | Lung Cancer Met... | Nivolumab Ipilimumab Evolocumab | 18 Years - | Duke University | |
| Capmatinib in Patients With Non-small Cell Lung Cancer Harboring cMET exon14 Skipping Mutation | NCT03693339 | Cancer Lung Cancer Met... MET Gene Mutati... | Capmatinib | 18 Years - | Asan Medical Center | |
| Phase 1 Trial of Endobronchial Ultrasound-Guided Transbronchial Needle Injection of Cisplatin for Stage IV Lung Cancer | NCT04311762 | Lung Cancer Met... | cisplatin | 18 Years - | University of Vermont | |
| I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy | NCT05537922 | Non Small Cell ... Lung Cancer Met... Lung Cancer, No... Lung Adenocarci... | 18 Years - | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | ||
| Stereotactic Ablative Radiotherapy for Oligo-Progressive Non Small Cell Lung Cancer | NCT04405401 | Lung Cancer Met... | SABR Standard of car... | 18 Years - | Centre hospitalier de l'Université de Montréal (CHUM) | |
| SBRT Combination With rhGM-CSF and Tα1 for Stage IV NSCLC Patients Who Failed in Second-line Chemotherapy | NCT02976740 | Lung Cancer Met... | SBRT Immunological A... Immunological F... | 17 Years - 70 Years | The First Affiliated Hospital of Xiamen University | |
| Safety of PDT-Photofrin® Prior to Lung Surgery | NCT03344861 | Lung Cancer Lung Cancer Met... | Porfimer Sodium Fiber optic | 18 Years - 79 Years | Concordia Laboratories Inc. | |
| Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC | NCT03057106 | Lung Cancer Met... | Durvalumab Tremelimumab Platinum-Based ... | 18 Years - | Canadian Cancer Trials Group | |
| Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers | NCT05860296 | Lung Cancer, No... Lung Cancer Sta... Lung Cancer Met... | SLC-391 pembrolizumab | 18 Years - | SignalChem Lifesciences Corporation | |
| A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib. | NCT03755102 | EGFR Gene Mutat... Lung Cancer Lung Cancer Met... | Dacomitinib Osimertinib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC | NCT03184571 | Lung Cancer Met... NSCLC Stage IV Adenocarcinoma ... | Bemcentinib; pe... | 18 Years - | BerGenBio ASA | |
| Anlotinib Versus Docetaxel as the Second-line Treatment in EGFR Wild Type Patients With Advanced NSCLC | NCT03703596 | Lung Cancer Lung Cancer Met... | Anlotinib Hydro... Docetaxel | 18 Years - 70 Years | Sichuan Cancer Hospital and Research Institute | |
| Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer | NCT04085315 | Lung Cancer Met... EGFR Gene Mutat... | Osimertinib Alisertib | 18 Years - | University of California, San Francisco | |
| NutriCare Plus a Medically Tailored Meal Intervention Among Patients With Lung Cancer | NCT04986670 | Lung Cancer, Sm... Lung Cancer Met... Lung Cancer Rec... Treatment Side ... Lung Cancer, No... Nutritional Imb... | Nutritional Cou... Medically Tailo... Nutrition Presc... Nutrition Asses... Nutrition Toolk... Monthly Emails | 18 Years - 100 Years | Tufts University | |
| Dendritic Cell Therapy for Brain Metastases From Breast- or Lung Cancer | NCT03638765 | Brain Metastase... Lung Cancer Met... Breast Cancer M... | DCVax-Direct | 18 Years - 75 Years | Northwest Biotherapeutics | |
| A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain | NCT05419076 | Lung Cancer Lung Cancer Met... Brain Metastase... Brain Metastase... Small-cell Lung... Small Cell Lung... | Stereotactic Ra... Cerebrospinal f... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib | NCT03076164 | Lung Adenocarci... Lung Cancer Lung Cancer Met... Lung Cancer Sta... Recurrent Lung ... Recurrent Lung ... | Trametinib Erlotinib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| SBRT Combination With rhGM-CSF and Tα1 for Stage IV NSCLC Patients Who Failed in Second-line Chemotherapy | NCT02976740 | Lung Cancer Met... | SBRT Immunological A... Immunological F... | 17 Years - 70 Years | The First Affiliated Hospital of Xiamen University | |
| Phase 1 Trial of Endobronchial Ultrasound-Guided Transbronchial Needle Injection of Cisplatin for Stage IV Lung Cancer | NCT04311762 | Lung Cancer Met... | cisplatin | 18 Years - | University of Vermont | |
| ANET Electrosurgery Applicator Pilot Evaluation Study | NCT03400748 | Lung Cancer Lung Cancer Met... | RF Ablation | 18 Years - | Olympus Corporation of the Americas | |
| Needlescopic-assisted Uniportal vs Uniportal VATS | NCT03439696 | Lung Cancer Lung Cancer Met... Bullous Disease... Nodule Solitary... Mediastinal Tum... | Thoracoscopic s... | 20 Years - 90 Years | National Taiwan University Hospital Hsin-Chu Branch | |
| Abscopal Effect of Radiation in Combination With rhGM-CSF for Metastatic Non-small Cell Lung Cancer | NCT03113851 | Lung Cancer Met... | Radiotherapy rhGM-CSF | 18 Years - | Peking University Cancer Hospital & Institute | |
| Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC | NCT04069936 | Non Small Cell ... Lung Cancer Lung Cancer Met... Lung Cancer, No... Non Small Cell ... NSCLC Non-small Cell ... Non-small Cell ... | MILs™ - NSCLC nivolumab tadalafil | 18 Years - | WindMIL Therapeutics | |
| PDR001 in Patients With Non-small Cell Lung Cancer Harboring KRAS/NRAS Mutation or no Actionable Genetic Abnormalities | NCT03693326 | Cancer Lung Cancer Met... Immunotherapy | PDR001 | 18 Years - | Asan Medical Center | |
| Feasibility Study of the RF Ablation Catheter to Ablate Lung Tumors | NCT03272971 | Lung Cancer Lung Cancer Met... Lung Cancer, No... | Radio-frequency... | 21 Years - 75 Years | Broncus Medical Inc | |
| Dendritic Cell Therapy for Brain Metastases From Breast- or Lung Cancer | NCT03638765 | Brain Metastase... Lung Cancer Met... Breast Cancer M... | DCVax-Direct | 18 Years - 75 Years | Northwest Biotherapeutics | |
| Anlotinib Versus Docetaxel as the Second-line Treatment in EGFR Wild Type Patients With Advanced NSCLC | NCT03703596 | Lung Cancer Lung Cancer Met... | Anlotinib Hydro... Docetaxel | 18 Years - 70 Years | Sichuan Cancer Hospital and Research Institute | |
| Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC | NCT03057106 | Lung Cancer Met... | Durvalumab Tremelimumab Platinum-Based ... | 18 Years - | Canadian Cancer Trials Group | |
| A Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Naïve Patients With Metastatic NSCLC | NCT05144529 | Lung Cancer Met... | Nivolumab Ipilimumab Evolocumab | 18 Years - | Duke University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
